Australasian Diabetes Congress 2020

In 1994, he was appointed Director of Public Health for Greater Glasgow Health Board and in 2005 he became Chief Medical Officer for Scotland. He was Knighted in 2011 and in 2014, the First Minister, Nicola Sturgeon, presented him with a lifetime achievement award for public service from the Scottish Government.

In April 2014 he became Professor of Global Public Health at Strathclyde University. In addition to research publication and supervision of doctoral students, Sir Harry leads on a number of major, multi-agency projects and is Chair of the University’s Centre for Health Policy. He is a regular invited keynote speaker to local, national and international events and to academic programmes. Among many appointments, he is a member of the Scottish Government’s Council of Economic Advisors; a member of Diabetes UK Board; Chair of the Wheatley Foundation; a member of Johnson & Johnson’s Impact Investment Advisory Committee and a member of the Health Foundation’s Sciana Programme for international health leaders.

His main clinical specialities are childhood diabetes and hypoglycemia. His research has focused on the growth and development of the pancreatic islets. He has also made important contributions in the field of congenital hyperinsulinism and neonatal diabetes. Lately, he has shifted his main area of interest into the use of human pluripotent stem cells and genome editing to study beta-cell pathophysiology.

Alex has established an extensive and unique research program focused on chronic disease in vulnerable communities, with a particular focus on outlining and overcoming health disparities. He leads projects encompassing cardiometabolic epidemiology, understanding the psychosocial determinants of chronic disease, mixed methods health services research, and trials of pharmacological and non-pharmacological chronic disease interventions. In July 2012, Alex joined SAHMRI to develop and lead a state-wide Aboriginal health research program. He leads a team of 52 staff, 29 of whom are Indigenous. He was recently admitted to the Australian Academy of Health and Medical Sciences.

Her work has been highlighted across national media outlets, such as NPR Science Friday and CNN, and has influenced both policy and practice. Her recent research focused on the underground exchange of diabetes medication and supplies due to high cost influenced the passing of Utah HB207, the strongest legislation in the nation to date focused on improving insulin access. Her research focused on online peer support that has influenced national recommendations in diabetes care. Dr. Litchman received her research doctorate and Master’s degree from the University of Utah College of Nursing. She is a Fellow of the American Association of Nurse Practitioners (FAANP), Research Committee Chair for the Association of Diabetes Care and Education Specialists, and member of the American Diabetes Association Therapeutic Inertia Research Committee.

She has contributed to the design and conduct of several major trials including REWIND, ODYSSEY 3a, SELECT, LENS, REMOVAL, CARDS and CANTOS. Professor Colhoun’s epidemiological research and clinical trials research have impacted on and been cited in clinical guidelines internationally and in national policy for diabetes. Professor Colhoun leads the large Scottish Diabetes Research Network Type 1 Bioresource research collaboration and the databasing and provisioning of national e-health record diabetes data to the Scottish Diabetes Research Network. During the COVID-19 epidemic she has Co-Chaired the COVID-19 Modelling & Research cell at Public Health Scotland. She has been a member of the Wellcome Trust Science Strategy Advisory Board, the JDRF Strategic Advisory Board and the Diabetes UK Clinical Studies Advisory Group.

Her lab was the first to map the kidney epigenome and catalogue genotype-driven gene-expression variation (eQTL) in human kidneys. Integration of GWAS, eQTL and epigenome data has been essential to prioritize disease-causing genes and variants.

Dr. Susztak generated the first unbiased, comprehensive kidney cell-type atlas using single cell transcriptomics. She identified that specific renal endophenotypes are linked and likely caused by the dysfunction of specific cell types.

In follow-up animal model studies, she conclusively demonstrated that MANBA, DAB2, DACH1 and APOL1 are new kidney disease risk genes. Her work established the role of proximal tubule cells, endolysosomal trafficking, metabolic and developmental pathways in kidney disease development.

Susztak's discoveries span genetics, genomics, epigenetics, molecular biology, physiology and nephrology, and have enormous translational relevance and considerable therapeutic potential.

Dr. Susztak has been the recipient of the 2011 Young Investigator Award of the American Society of Nephrology and American Heart Association; one of the most prestigious award given to researchers under the age of 41 in the field of nephrology. Her laboratory is supported by the National Institute of Health, the American Diabetes Association, the Juvenile Diabetes Research Foundation and private sources.

“I think this is a really exciting time in science. New technologies are emerging, which will really accelerate research progress, and I think we have fantastic new discoveries ahead of us in biology.”

Over her career, Professor Apte has served in several senior leadership positions at Faculty, University and Discipline levels, including as Editor-in-Chief of the journal Pancreatology. Professor Apte’s contribution to medical research, tertiary education and the community have been recognised by several major awards in recent years including the Medal of the Order of Australia (OAM) in 2014, the 2015 NSW Premier's Award for Woman of the Year, the Gastroenterological Society of Australia’s Distinguished Researcher Prize (a prestigious recognition by the peak national body for the Discipline of Gastroenterology) in 2018, and being elected as a Fellow of the Australian Academy of Health and Medical Sciences in 2019.

With NHMRC project grant funding, she established the ANZ Diabetes and Cancer Collaboration (ANZDCC) dataset which is a collaboration of 18 Australian cohort studies with the aim to examine the relationship between diabetes, obesity, metabolic syndrome and hypertension. Her more recent work involves exploring the trends in diabetes incidence and mortality across the globe and heads a consortium of 23 collaborators to do this work.

As a part of this broader area, she also works on the other large datasets such as the National Diabetes Service Scheme (NDSS) linked to administrative data. Work on the NDSS has led to international status attested by invitations to the Diabetes and Cancer consortium, editor roles at Diabetes Research and Clinical practice and Atherosclerosis, the presidency of the International Diabetes Epidemiology Group in 2015-2017 and to co -chair the current edition (10^th) of the Diabetes Atlas for the International Diabetes Federation.

Professor Magliano has strong epidemiological and biostatistical skills. Fifteen years of teaching of epidemiology for Monash University has meant that her conceptual skills in epidemiology are current. Furthermore, as the senior epidemiologist of the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) for over 15 years, she has acquired real life epidemiological training by working directly in the field, conducting epidemiological analyses. In 2017 she was awarded a NHMRC Senior research fellowship and the Australian Jeff flack data award from the Australian Diabetes Council.

He is a visiting medical officer at the Royal Hospital for Women, Sydney, Australia where he is Director of the Sydney Menopause Centre and the Barbara Gross Research Unit. Until recently he worked at the Moree Aboriginal Health Service. John is a Director of the Women’s Health and Research Institute of Australia (WHRIA). This is a private clinic located in Bathurst St, Sydney which has a large multidisciplinary group of health practitioners offering clinical and research services. He is a member of the Breast Cancer MDT at Prince of Wales Hospital Randwick.

His research and clinical interests include managing menopause after breast cancer, infertility, early menopause, polycystic ovary syndrome (PCOS), amenorrhoea, osteoporosis, PMDD, biofilms, hormone replacement therapy as well as herbal medicine.

In 2007 Melkam moved to Canada for postdoctoral training at Montreal Diabetes Research Centre where she worked to characterize the regulation and role of the fatty acid receptor, GPR40 in β-cells in Professor Vincent Poitout’s laboratory. In 2012 Melkam joined Professor Alan Attie’s laboratory at the University of Wisconsin for her second post-doctoral fellowship. In the Attie laboratory Melkam studied the involvement of Sorcs1 in the formation and stability of insulin secretory granules. In 2015, Melkam returned to Australia to establish her independent career at the Charles Perkins Centre, University of Sydney. Her lab aims to understand the mechanisms behind insulin secretory granules biogenesis, maturation, stability and secretion.

His group studies i) men with low testosterone, ii) patients with hormone sensitive cancer to understand how reproductive hormones regulate musculoskeletal health and glucose homeostasis.

He has >150 publications and book chapters with >7,000 citations.

Editorial board memberships: Journal of Clinical Endocrinology Metabolism, Journal of the Endocrine Society, Clinical Endocrinology; Associate Editorship, Asian Journal of Andrology.

Committee memberships: US Endocrine Society Endocrine Self-Assessment Program (ESAP); Endocrine Society of Australia Council.

In 2018, Dr Montgomery moved to the University of Melbourne, where she is currently investigating links between perturbations in liver homeostasis and the development of type 2 diabetes, with a special focus on liver-secreted proteins and their effects on glycaemic control.

Her long-term vision has been to characterise these novel immune factors and manipulate them therapeutically using pre-clinical models of immune-driven pathologies. She holds a patent for targeted immunotherapy in metabolic disease which has led to the formation of a spin-off company, Jetra Therapeutics and venture capitalist funding to progress this in Fatty Liver Disease. She has a rapid upward trajectory in research, evident by extensive body of high-quality publications including in Nature Medicine, Oncogene and Gastroenterology. She has been awarded more than $4 million in competitive funding and has won 21 awards to date, including an award from the Children’s Health Foundation in 2019 and the QLD Tall Poppy Award 2020. She is an associate editor for the Clinical and Translational Immunology Journal (impact factor 7.2). She is a well-recognised emerging leader in the field as evidenced by a recent invitation to chair at the Immunology 2020 conference by American Association of Immunology.

For six years, she worked as a researcher at the Australian Centre for Behavioural Research in Diabetes (ACBRD), studying the psychological, social and behavioural aspects of living with type 1 and type 2 diabetes. Her special interest and knowledge in diabetes and health psychology helped establish her private psychology practice. Adriana currently consults at OPTIMIND, a multidisciplinary mental health private practice on the Mornington Peninsula in Victoria, and she also offers telehealth services to people with diabetes from around the country.

In 2012, she joined Inserm unit 1190 - Translational Research for Diabetes, at The University of Lille, on a post-doctoral fellowship to pursue an independent research project on insulin-independent regulation of glucagon secretion with and without current drug therapies using human islets ex-vivo and mouse models of diabetes. She is currently a group leader at Institut Pasteur de Lille continuing in deciphering the mechanisms by which antihyperglycemic drugs regulate glucose homeostasis and normalize pancreatic hormone secretion in diabetes.

She has previously held positions as Manager of Diabetes Education at Diabetes Victoria and Director of Education at the International Diabetes Institute in Melbourne, and Research Fellow at the Australian Centre for Behavioural Research in Diabetes and Monash University in the NHMRC CRE in Patient Safety and Department of Health Science. Virginia’s research interests include diabetes self-management and structured education, diabetes distress and psychological wellbeing, particularly among adolescents with type 1 diabetes. She has 17 peer-reviewed publications related to these areas of research.

She currently also serves as a member of the Diabetes and Endocrine Network- Agency of Clinical Innovation (NSW Health) and was the founder of the PEACE conference. Dr. Howari speaks nationally & internationally on public and health industry platforms and is a freelance writer for health publications. Having lived with type one diabetes for over 27 years she incorporates a unique medical and personal perspective in her proactive educational roles with various institutions and public health sectors. As a media commentator, Dr. Howari has also been interviewed in health magazines, print media, radio, on screen and social media.

Dr. Eckel is past president of the American Heart Association, the Obesity Society and the Association of Patient Oriented Research and is currently president of Medicine and Science of the American Diabetes Association. He Co-Chaired the 2013 ACC/AHA Lifestyle Guideline for Prevention of Cardiovascular Disease (CVD) and was a member of the 2013 ACC/AHA Cholesterol Guideline Committee. Dr. Eckel has published nearly 400 articles in peer-reviewed journals and his translational research has used populations, human subjects in the General Clinical Research Center and Clinical Translational Research Center, genetically-modified mice, molecular techniques and tissue culture to pursue mechanistic pathophysiological relationships between metabolic disorders such as obesity/metabolic syndrome/diabetes and CVD.

She reviews new procedures and technology in relation to best diabetes practice implementing state-of-the-art equipment to our hospitals. Irene lectures at the University of Sydney and UTS in both undergraduate and post graduate courses for medical and nursing students. She was the course coordinator at UTS for the Master of Nursing, Nurse Practitioner and The Graduate Certificate in Diabetes Education and Management 2012-2014. Irene is also co-chair of the ACI Diabetes and Endocrine Network.

He co-founded the Australian start-up biotech company Continuum Biosciences in 2017. His laboratory investigates the pathophysiology and treatment of obesity-related disorders including fatty liver disease and obesity-related cancers.

This exploratory work has informed Marian’s current PhD research project at Curtin University. Marian was the recipient of the 2018 Australian Diabetes Research Foundation, Research Fellowship. Her current research interests are facilitating physical activity in the type 1 diabetes population, using structured group education.

She was amongst the first in the world to study the role of fetal programming of early onset metabolic disorders and CKD progression. Her current work examines the effect of maternal influences including obesity, smoking and particulate matters on offspring predisposition to CKD and epigenetic regulation in disease development. She is also developing a novel tool for early diagnosis and examining the effect of novel natural and pharmaceutical therapies for glycaemic control, and renal fibrosis

I have had a number of opportunities to undertake research in both urban and remote communities across the Northern Territory and the Kimberley. I have worked at Menzies School of Health Research for over 11 years across several divisions, including Child Health, Wellbeing and Preventable Chronic Disease, and Tropical and Emerging diseases. During this time, I have been able to connect with participants and build strong relationships based on trust and respect, as well as build on my capacity as a researcher.

In 2016, I had the opportunity to do some qualitative work conducting in-depth interviews with women who had diabetes in pregnancy. This was a lightbulb moment for me where I realized that this is what I am meant to be doing – creating a space that enables Aboriginal and Torres Strait Islander peoples voices to be heard within research. This has been my newfound passion within research.

I believe as Aboriginal and Torres Strait Islander researchers we are accountable not only to our institutions but to our people and our communities. It is our role to be the link between community and institutions. It is our role as Aboriginal and Torres Strait Islander researchers to empower our people and give a voice back to Aboriginal and Torres Strait Islander communities.

I am dedicated and committed to working towards improving health outcomes for Aboriginal and Torres Strait Islander people. I believe that it is my responsibility as an Indigenous researcher to advocate for Aboriginal and Torres Strait Islander people and their rights. I believe Aboriginal and Torres Strait Islander people must play an imperative role in research, and we need to work together collaboratively to ensure Aboriginal and Torres Strait Islander people have an opportunity to provide input into the direction of our research.

His research focusses on improving outcomes for people living with viral hepatitis. He was involved in the discovery of IL28B polymorphism as a predictor of treatment outcome in HCV, and is an active clinical investigator for trials evaluating the efficacy of novel antiviral DAA regimens. With the development of DAA therapy for HCV, he has more recently been actively pursuing the development and evaluation of new models of care for people with HCV, with a focus on prisoners and treatment as prevention to eliminate transmission and reduce prevalence of HCV in Australia. He has published widely in journals including Nature, New England Journal of Medicine, Journal of the American Medical Association, Gastroenterology, Hepatology, Gut and Journal of Hepatology.

In 2020, Benoit joined Prof. Mark Febbraio’s laboratory at the Monash Institute of Pharmaceutical Sciences as a postdoctoral researcher where he will submerge himself in the NAFLD field with a focus on NASH-induced hepatocellular carcinoma.

She is an elected member of the Australian Dietetic Council. In 2019 she was awarded the Michelle Beets award for outstanding achievement in advancement of children’s health and the Hunter Children’s Research Foundation Researcher of the Year.

Her work focuses on dissecting appropriate cellular targets in cancer and identifying novel therapeutic strategies to treat prostate cancer. Her team is internationally-recognised for expertise in patient-derived xenografts (PDXs), which in collaboration with her urology, pathology and oncology colleagues, provides a strong translational approach to address clinically relevant questions. More recently, her team has focused on elucidating the endocrine and metabolic changes that contribute to prostate cancer disease progression including fatty acid metabolism.

As well as her clinical role Cheryl has a strong focus on Health Professional education for nurses, allied health, medical practitioners and students. Cheryl is a member of the clinical advisory committee for Diabetes Victoria, a member of the Medical, Education and Scientific Advisory Board for Diabetes Australia. Cheryl lives with Type 1 diabetes which she manages with a DYI closed loop pump.

Evangeline is passionate about communicating nutritional and food science to the public either as an invited speaker at public events or on radio or television, she is also an author and contributor to The Conversation with over 1.1 million reads. Evangeline's research interests include omega-3 fatty acids, the Mediterranean Dietary pattern for chronic diseases, Sports Nutrition and the Environment-Food nexus.

Her current research continues to explore maternal metabolism, with emphasis on the role of the microbiome.

Heather has worked across several research studies, including the ENDIA study, as a research midwife at the Child Health Research Unit at Barwon Health up until 2016. In addition to her role as a hospital midwife, Heather is the director of Hearten Breastfeeding and Parenting Support – a private IBCLC and childbirth education service in Geelong, Victoria. Heather is also currently completing a Master of Public Health degree at the University of Melbourne.

At UoM, Jennifer’s PhD evaluated the role of the renin-angiotensin aldosterone system in kidney disease, and as a post-doc she moved into the field of diabetic complications and established the Diabetic Retinopathy Laboratory. Interested in inflammation and diabetes, she moved to Monash University to interrogate the contribution of the adaptive immune system and particularly regulatory T cells to neovascular retinopathies including diabetic retinopathy. Jennifer’s research is supported by the NHMRC, JDRF, Diabetes Australia and the CASS Foundation. Jennifer has a long history of working with national and international pharmaceutical companies with the view to clinical translation.

She also co-directs the Children’s Diabetes Centre at Telethon Kids Institute, an integrated Clinical and Research centre, which has exercise as one if its key research themes. She is a past president of the professional society, Australasian Paediatric Endocrine Group.

The partnership includes several large NHMRC-funded projects, including the Northern Territory and Far North Queensland Diabetes in Pregnancy Partnership and The PANDORA (Pregnancy And Neonatal Diabetes Outcomes in Remote Australia) Cohort Study. After completing the majority of her physician and endocrinology training at St Vincents Hospital Sydney, Louise moved to Darwin in 2002 to pursue her passion for improving the health of Indigenous Australians. Louise is currently on the Australian Diabetes Society Council and was previously a member of the Council of the Australasian Diabetes in Pregnancy Society. Louise has been providing clinical diabetes services to urban and remote NT communities for over 18 years, including via telehealth.

Nicole also runs a corporate nutrition service for Australia’s largest EAP Provider, Benestar, established in 2014, which specialises in assisting employees with weight management and chronic diseases such as diabetes. Nicole is a guest lecturer for The University of Sydney & University of New South Wales and is a media spokesperson for Dietitian’s Australia. Prior to becoming a dietitian, Nicole worked as a senior manager in the chronic disease management division for Merck, Sharp & Dohme (MSD) pharmaceuticals.

Her current clinical and research interests include pregnancy-related issues in women with renal disease, including all stages of CKD, dialysis and transplant patients, living kidney donors and women with hypertension. She also chairs the CNARTS Clinical Research Group which leads a range of studies addressing patient-centred outcomes in CKD and dialysis patients. Dr Jesudason has been the Clinical Director at Kidney Health Australia since June 2017.

She has been actively involved in various committees both for the ADEA and Dietitians Australia and is a trained DESMOND & SMARTs educator for Diabetes Australia. Her passion for education and training community health workers, nurses and other health care professionals has seen her involvement in a number of diabetes-related international projects including the World Diabetes Foundation project in Papua New Guinea, Diabetes Training and Awareness Project in Kiribati, Pacific Islands and Aus-Aid funded Diabetes training project in India. Her research interests and projects have been presented at state, national and international conferences.

Her two main areas of research include improving the care of children with diabetes and adolescent girls with polycystic ovary syndrome. Dr Peña initiated and led a multidisciplinary evidence based guidelines development group that developed and published the first Australasian Guidelines for assessment and management of children with Type 2 diabetes.

He is currently trying to return to the clinic with human beta cells differentiated from pluripotent stem cells that are seeded into an immunoisolatory bioengineered device and implanted subcutaneously. Dr Tuch spends his non-clinic time in academia (he is a Professor at the University of Sydney and Monash University), the not-for-profit sector (Australia Foundation for Diabetes Research, and NSW Stem Cell Network) and the commercial arena (Living Cell Technologies Ltd).

Renae chairs the Menzies-wide youth working group and in 2019 initiated and led the Northern Territory Youth Health Summit. Renae is also jointly teaching the Qualitative Research Methodology Unit for Menzies’ Master of Public Health.

She is also the Head of Diabetes at Austin Health, where she co-ordinates the clinical care of inpatients and outpatients with diabetes. She heads diabetes and obesity clinical trials at CREDO-Centre for Centre for Research and Education in Diabetes and Obesity and has over 135 publications in leading diabetes and endocrinology journals and has obtained a total of over $7.5 million of research funding, including a recent NHMRC Clinical Trials and Cohort Studies grant.

His awards include the IDEG Peter Bennett award (2011), the ADS Jeff Flack Diabetes Data award (2015), and the ADS Kellion Diabetes award (2018). He has authored over 400 peer-reviewed scientific papers and 35 book chapters, was included in the Thomson Reuters The World’s Most Influential Scientific Minds (2014) and the Clarivate list of the world’s most Highly Cited Researchers (2017 and 2018).

She lives in rural Victoria, Australia with her beloved alpacas, Westie dog and husband John, where she dabbles in gardening and writes short stories.

My professional qualifications are NSW registered nurse/midwife with a Bachelor of Nursing from the University of Newcastle (1993), and a Masters in Applied Management (Health) through the University of Newcastle and a Certificate 4 in Learning and Assessment.

In Colorado, and then Seattle, he and his team published methods to reduce nocturnal hypoglycaemia after exercise, to improve the quality of exercise education in paediatric diabetes clinics, how fear of hypoglycaemia may impact exercise, and how well youth with type 1 diabetes follow safety guidelines around exercise. He is a co-author of two international consensus statements on exercise and type 1 diabetes. In 2019 he returned to Australia to join the team at Perth Children’s Hospital and Telethon Kids Institute, with the goal to incorporate systematically evaluated physical activity level into the standard of care for all youth with T1D.

He is also involved in the HRFS Accreditation program. Joel is currently undertaking a PhD at the Garvan Institute of Medical Research, which includes a novel randomised clinical trial for people with acute Charcot foot across nine public teaching hospitals. He has presented his research at national and international meetings. Joel also co-founded the Sydney Diabetic Foot Interest Group (SyD FIG) in 2019, an inter-institutional and inter-disciplinary case based meeting held quarterly.

Throughout his career, Prof Maberly has focused on fostering public-private-civic partnerships and bring public health evidence-based research findings to large scale implementation.

She then worked in community-based diabetes education with Tasmanian Divisions of General Practice, Medicare Local and Primary Health Tasmania. Since 2016 Elisa has been Clinical Manager with Diabetes Tasmania based in Northern Tasmania. She has been part of a working group on aged care for the last 3 years which is a pilot program to improve outcomes for residents with diabetes in Aged Care facilities.

She then worked in community-based diabetes education under Primary Health and for the last 4 years has been with Diabetes Tasmania based in the North West Coast of Tasmania running clinics and groups. She has been part of a working group on aged care for the last 3 years which is a pilot program to improve outcomes for residents with diabetes in Aged Care Facilities.

She was on the Editorial Board for Diabetologia >8 years, and serves on the editorial boards for Diabetes, Clinical Science and the Australian Internal Medicine Journal. Previously, she has been President of the Australian Atherosclerosis Society (2012-14). She was awarded fellowship of the Australian Academy of Health and Medical Sciences (2018) and is now the chair for the Victorian AAHMS selection committee. In 2019, she was awarded the prestigious Leibniz Chair at the German Diabetes Centre, Leibniz Centre for Diabetes Research at the Heinrich Heine University, Dusseldorf, Germany.

Katherine has had a long interest in diet and weight optimisation for diabetes prevention and treatment, particularly in people with severe mental illness. Another significant interest in how diabetes adversely affects cognition preventing this, both in clinic and in research, about which she will talk to us today.

She is a past president of the Australasian Menopause Society and immediate past President of the International Menopause Society. She has over 420 peer-reviewed publications and in numerous awards. Her contributions to endocrinology were recognised by the Australian Endocrine Society Senior Plenary Award (2019) and the International Excellence in Endocrinology Laureate Award of the Endocrine Society USA (2015).

Currently he serves on the editorial boards of Autonomic Neuroscience - Basic & Clinical, the Journal of Neurophysiology, and the American Journal of Physiology. In 2011, along with Ida Llewellyn-Smith, he co-edited Central Regulation of Autonomic Functions. His research has examined supramedullary circulatory control mechanisms, central cardiovascular reflex pathways, central control of pancreatic secretion and brain control of glucose homeostasis during hypoglycaemia.

Her work includes co-development of the Rapidcalc iPhone dose calculator, development of the rapid insulin dosing card that has become the standard tool used by all children with T1DM and contribution to the Dose Adjustment for Normal Eating (DAFNE) program at all levels, from the introduction of the program in 2005, subsequent facilitation of the program over 10 years and ongoing contribution to curriculum review and representation on the DAFNE advisory group. Brigid’s PhD focused on intensive management strategies and education for T1DM and she remains focused on improving self-management education for flexible insulin therapy. Brigid’s work life is now split between diabetes clinic at the QCH and her private practice, TIPS for Diabetes and Brisbane Endocrine.

She obtained a Diploma in O&G whilst in the UK. Upon returning to Australia she undertook a PhD in Andrology at Prince Henry's Institute with the subject of her thesis the effect of ageing and body composition on androgens in the male, and the role of testosterone therapy on body composition and markers of cardiovascular risk. She maintains clinical and research interests in the field of male reproductive endocrinology.

Claire is Scientific Director of the Adelaide SCOPE and STOP pregnancy cohorts and has developed algorithms for use as screening tools to predict which women are at risk of developing major pregnancy complications including gestational diabetes She has a particular interest in modifiable risk factors for poor health in pregnancy and beyond. She has over 200 refereed publications and has won more than $25million in grant funding.

He is also supported by a Department of Medicine, University of Toronto Merit Award. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardiorenal axis in diabetes. His research group is also involved in early and late phase clinical trials in the cardiorenal-metabolic field, including several primary renal outcome trials in patients with and without diabetes. Dr. Cherney’s research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and cardiovascular disease. In 2019, he received the American Society of Nephrology (ASN) Distinguished Researcher Award for outstanding contributions to nephrology. In 2019 he also received the Diabetes Canada/CIHR - Institute of Nutrition Diabetes and Metabolism (INMD) Young Scientist Award.

She has been Lead Endocrinologist of the Diabetes and Pregnancy service at RPAH for over 30 years. She was on the Australasian Diabetes in Pregnancy Society (ADIPS) Council from 1991-1998 and 2002-2010 (President 2008-2010). She is involved in the teaching programs of the Australasian Colleges of Anaesthetics, Obstetrics & Gynaecology, and Physicians, as well as education programmes for General Practitioners and Midwives.

He is currently Director of the Freemasons Centre for Men’s Health and Wellness, University of Adelaide, Senior Consultant Endocrinologist Royal Adelaide Hospital, and Senior Principle Research Fellow at South Australian Health and Medical Research Institute. He is a Fellow of the Australian Academy of Health and Medical Sciences. His research interests relate to mechanisms, consequences and management of obesity and related disorders, particulary in men. He has published over 400 research papers, book chapters, invited reviews and expert reports.

Her research interests include improving preconception care pathways, maternal dietary intake, expanding access to diabetes technology and evaluating automated closed-loop insulin delivery systems in type 1 diabetes pregnancy. Her research, which is funded by Juvenile Diabetes Research Foundation (JDRF), Diabetes UK, and the National Institute for Health Research (NIHR) is changing the management of diabetes in pregnancy with landmark publications in leading clinical journals. She is an associate editor for Diabetologia, chairs the UK National Pregnancy in Diabetes (NPID) group which is the largest ‘real-world’ audit of diabetes in pregancy and serves on a number of national and international research funding, trial steering and data monitoring committees.

Jane has published 160+ articles in peer-reviewed journals, two books, several book chapters, and 220+ conference abstracts. Google Scholar indicates there have been >6,200 citations of her work, and she has an H-index of 35, an i10-index of 106. In 2018, she was honoured to be profiled in the Lancet Diabetes & Endocrinology: ‘Jane Speight: tackling diabetes and its stigma Down Under’. In 2019, her profile was featured by The Lancet in a virtual collection to mark International Women’s Day: #LancetWomen. Jane has been an investigator on numerous trials and research programmes, which have attracted total research funds of over $71 million.

She is currently pursuing a research fellowship in Pediatric Diabetes at The Children's Hospital at Westmead in Sydney under the mentorship of Prof Maria Craig and Prof Kim Donaghue.

As a result, her team have developed approaches for directing the differentiation of human pluripotent stem cells to human kidney organoids. Her group are applying this knowledge to disease modelling, drug screening, cell therapy and tissue engineering. Professor Little is an NHMRC Senior Principal Research Fellow at MCRI, Program Leader of Stem Cells Australia and Professor, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne. Melissa is also President Elect of the International Society for Stem Cell Research, and immediate past President of Australasian Society for Stem Cell Research. A Fellow of the Australian Academy of Science and the Australian Academy of Health and Medical Sciences, Professor Little’s work has been recognised by many awards, including the GlaxoSmithKline Award for Research Excellence (2005), AAS Gottschalk Medal in Medical Sciences (2004), Eisenhower Fellowship (2006), ANZSCDB Presidents Medal (2015), Boerhaave Professorship, Leiden University (2015), UNSW Eureka Prize (2016) and the NHMRC Elizabeth Blackburn Fellowship Biomedical (2018), Honorary Doctorate, Leiden University (2019), the prestigious Alfred Newton Richards Award (2019), and the Julian Wells Medal (2020).

Through looking at system and service gaps, making strategic decisions and trialling innovative methods to create change, Natalie helps to translate health priorities and strategy in the pursuit of improved diabetes service delivery and the support of people living with diabetes. She shares her knowledge of these areas through regular journal articles, publications and presentations nationally and internationally.

She is on the Patient Advisory Council for HypoRESOLVE, a member of the OPEN Diabetes Project, and is an AI for the NHMRC CRE in Digital Health. Renza has extensive experience as a facilitator, presenter and media spokesperson and is frequently invited to speak at conferences locally and around the world. She speaks about topics including peer support in diabetes management, diabetes technology, and why language matters in diabetes and healthcare. Renza is well-known in the diabetes online community, and is well-versed in social media, its use and impact on people with chronic health conditions and application in peer support. She is the author of Diabetogenic, (www.diabetogenic.wordpress.com) and a regular contributor to many online and print publications. Since August 2017, Renza has been wearing a DIYAPS and is active in the #WeAreNotWaiting movement.

Professor Stanton holds current NHMRC and Heart Foundation research grants and regularly reviews grants for both funding bodies. He is one of the current Cardiac Imaging Section Editors of the Heart, Lung and Circulation journal.

Sophia has over 220 publications in peer-reviewed journals including New England Journal of Medicine, Lancet, Annals of Internal Medicine, British Medical Journal, and Nature Reviews, and contributed to clinical care guidelines for the American Diabetes Association, Kidney Disease Improving Global Outcomes Organisation and Australian Living Evidence for Diabetes Consortium.

He has been instrumental in establishing the Royal Prince Alfred Diabetes Centre as an International Diabetes Federation “Centre of Education” and National Association of Diabetes Centres “Centre of Excellence”.

Professor Kay is a fellow of the Australian Academy of Health and Medical Sciences, a Director of the Association of Australian Medical Research Institutes, Secretary of the International Pancreas and Islet Transplant Association and the immediate Past President of The Immunology of Diabetes Society.

He is married to gastroenterologist Dr Barbara Demediuk, and they have four children.

Anna is also employed by the University of Melbourne in academic teaching, involving clinical skills coaching and lecturing at the St Vincent’s Clinical School. She is a member of the Royal Australasian College of Physicians, Australian Diabetes Society, Endocrine Society of Australia and the Endocrine Society (USA).

He has established an integrated model of care for the management of complex Type 2 diabetes, established a telehealth service delivering Endocrine services to a number of centres in rural and remote Queensland and tested the use of mHealth technology in a new model of care in a tertiary diabetes service. Tony currently sits on council of the Australian Diabetes Society. He is Chair of the National Association of Diabetes Centres (NADC) and honorary Chair of the Models of Care subgroup of the NADC.

He is recognized for his work on the molecular physiology of glucose transporters and of gluco-incretin receptors, which he initiated by the first cloning and functional characterization of the beta-cell glucose transporter Glut2, and of the pancreatic beta-cell GLP-1 receptor. These original discoveries led him to investigate the role of glucose sensing mechanisms in the control of glucose homeostasis. His present research focuses on how brain glucose-sensing neurons control glucose homeostasis through the regulation of autonomic nervous activity and of pancreatic alpha and beta-cell function, and how these neurons control feeding behavior. In parallel, he investigates novel intracellular signaling pathways that control pancreatic beta-cell mass and function, in particular in response to gluco-incretin hormones and metabolic stress. His work has been funded by several Swiss and European grants, including Advanced Research Grants from the European Research Council and network grants from the Innovative Medicine Initiative, which he coordinated, and by the JDRF. He served as vice-president of the EASD (2012-2015). He is an elected member of the Research Council of the Swiss National Science Foundation and of the Swiss Academy of Medical Sciences. His work has been recognized with several national and international awards, including the 2009 Albert Renold Award from the EASD for his work on pancreatic beta-cells and the 2017 Claude Bernard Award from the EASD for his lifetime achievements in the field of diabetes research.

She is a member of the Statewide Diabetes Clinical Network, Type 1 Diabetes Working Group. She has been involved with the distribution of the DPAT throughout Queensland. She is also a member of the committee developing the Statewide Guidelines for Assessment and Management of Disordered Eating in persons with Type 1 Diabetes. She is a Senior Lecturer with the University of Queensland.

She is a Certified pump trainer (CPT) for Medtronic, AMSL and Ypsomed insulin pump (CSII) therapy. She is also an expert in all forms of CGM. Her over riding passions are for working with Type 1 diabetes, Type 1 women and pregnancy, & CSII, Continuous Glucose Monitoring, GDM and steroid induced diabetes. Sue has worked in many areas of research most recently being the Research Nurse Coordinator of the Hybrid Closed loop insulin pump study with Melbourne university. Sue is a strong advocate for Telehealth in the area of Diabetes education having been practicing via Zoom throughout the Covid 19 shutdown with her clients. Sue is a registered Mentor with the ADEA and loves to help young diabetes educators reach their full potential.

To date he has 221 publications (including 174 original research articles) with >5,000 citations. He has a special interest in testosterone in male ageing, and the relationship between testosterone and cardiovascular risk in middle-aged and older men. Bu chairs the Endocrine Society of Australia’s Medical Affairs Committee. He was first author on the ESA Position Statement on Management of Male Hypogonadism published in the MJA in 2016. He was an investigator in the Testosterone for the Prevention of Type 2 Diabetes Mellitus (T4DM) study, an Australia-wide randomised controlled trial of testosterone to prevent or revert type 2 diabetes in men.

Her major interest is in the psychological consequences of hypoglycaemia; and in people with diabetes perceptions of new treatments and technologies. In addition to her research Christel is actively involved in training diabetes health professionals in how to address the emotional aspects of living with diabetes. She is the first author of ‘Diabetes and emotional health: A handbook for health professionals supporting adults with type 1 or type 2 diabetes’ which was part of the National Diabetes Services Scheme National Development Programme for Mental Health and Diabetes (2012-2016).

A/Prof Simeonovic has over 30 years experience in Type 1 Diabetes (T1D)-related research and leads the Diabetes/Transplantation Immunobiology Laboratory, Department of Immunology and Infectious Disease at the John Curtin School of Medical Research, ANU. Her early research interests focussed on the immunobiology of pancreatic islet allo- and xeno-transplantation. Her research focus has since moved to understanding the autoimmune destruction of islet beta cells during T1D development in mice and humans. Highlight discoveries include identifying the peri-islet basement membrane as a conventional basement membrane containing perlecan (a heparan sulfate proteoglycan (HSPG)), the unusual localisation of other heparan sulfate proteoglycans (e.g., collagen type XVIII, a conventional “extracellular” matrix component) inside islet beta cells, the critical role for heparan sulfate (HS) in the survival of islet beta cells and a critical role for the HS-degrading enzyme heparanase in T1D development. Studies in the Simeonovic lab have suggested that a decline in beta cell HS represents a common pathway contributing to beta cell loss in autoimmune T1D and in Type 2 diabetes (T2D; a “metabolic syndrome” disease), albeit via different mechanisms. These discoveries underpin a new paradigm for understanding the molecular basis of beta cell health and disease. A/Prof Simeonovic is currently investigating novel circulating innate immunological biomarkers of beta cell damage in T1D.

His research activities include the responsibility for establishing the Diabetes Technology Research Group in the clinical trials unit with the University of Melbourne Department of Medicine at St. Vincent’s Hospital. His research interests include investigator initiated and sponsor lead clinical trials involving the evaluation of new technologies in the management of patients with diabetes and their interaction with the technology. He is the Chief Investigator for the JDRF funded study examining the long-term clinical impact of an artificial pancreas. He has research collaborations with clinicians and industry both in Australia and internationally.

She currently works as a diabetes educator in private practice providing diabetes education services in several GP practices, and as a diabetes educator at the Womens Hospital in Melbourne. Volunteer roles include Chair of the ADEA Vic branch exec and mentoring diabetes educators doing the guided self-determination course.

She has extensive experience delivering programs and training to Community members in urban, regional and remote areas of Queensland and the Torres Strait, including staff from Aboriginal Medical Services, Primary Health Networks, Correctional Services, Queensland Health and other organisations, both government and non-government. Her previous roles included facilitating the B.strong training for the Menzies School of Health Research, and delivering culturally appropriate diabetes education programs to Community members and health practitioners for Diabetes Queensland. Her work with the Australian Diabetes Educators Association, Indigenous Allied Health Australia and the National Aboriginal and Torres Strait Islander Health Worker Association resulted in the opportunity for Aboriginal and Torres Strait Islander Health Workers, who had completed the Graduate Certificate in Diabetes Education and Management, to qualify for credentialing as diabetes educators. Grace believes that culturally appropriate education and programs plays an important role in improving health outcomes for First Nations people.

Helen chairs the group developing the Guidelines for Disordered Eating as part of the Queensland Diabetes Statewide Diabetes Clinical Network, Type 1 Diabetes Working group. She is an accredited OzDAFNE, DESMOND and SMARTS facilitator.

She is an Australian Diabetes Society council member and their ADC POC chair and editor for journals including Kidney International. She has published >200 publications with >11000 times. She has received numerous awards including the Commonwealth Health Minister’s Award for Excellence in Medical Research.

Kate is also co-author of The Low GI Guide to Managing PCOS, The Low GI Vegetarian Cookbook, Low GI Gluten-Free Living, and The Bump to Baby Diet, and has authored a number of textbook chapters on PCOS, pregnancy and vegetarian nutrition. Kate has a particular interest in vegetarian nutrition and plant-based diets, and the dietary and lifestyle management of diabetes and polycystic ovary syndrome. She is passionate about the role of plant-based diets in the prevention and management of type 2 diabetes and will be speaking on this topic at the ADC.

As part of her work in the area of diabetes she has a great deal of experience in carbohydrate counting, insulin pump therapy and continuous glucose monitoring. She has presented widely at many meetings and conferences on these topics. She is currently the study dietitian for St Vincent's Hospital Melbourne for the ORACL study.

Kirstie is the recipient of the DAA Joan Woodhill Prize for Excellence in Research & Young Achiever of the Year for 2018. Her work has changed clinical practice and has been incorporated into international diabetes guidelines including the American Diabetes Associations’ Standards of Medical Care. She serves as the Chair of the ADEA Program Organising Committee for the ADC.

Leanne has seen a lot of treatment changes in this time and is keen to be on the cutting edge, making these treatments work for her to get the best control she can. Her drive to be involved in research comes from a desire to see the best emerging technologies become available to others with diabetes in Australia. She was the first person in Australia to commence on the 670G ‘Closed loop’ trial and might have driven the research team slightly mad sending frequent photos of her CGM trace in the first week of ‘closing the loop’ and threatening to not give it back. When she’s not hooked up to a range of medical equipment, being bled for science, or being monitored remotely in her sleep from the other side of the world she can be found plotting her next overseas trip with her husband, having weekends away with friends or pursing her creative passions of cooking and handcrafts.

Supported by international research funding, Sybil is now enthusiastically investigating insulin pump therapy, exercise, sleep, nutrition, psychosocial well-being and advancement of closed-loop automated insulin delivery. Sybil strives to integrate diabetes technology research with delivery of clinical care embracing technology.

She has also worked in both community and acute care areas as well as clinical research. Her Professional Interests include; Integration and translation of evidence-based research into organisations, Quality improvement through research projects, Diabetes Management and the older person, Medication in aged care, Coaching and mentoring of staff as an education tool.

Prof. O’Brien later moved to Monash Medical Centre where he spent 15 years as Head of Diabetes, returning to the Austin Hospital in 2007 to take up his current position. His research work has focussed mainly on diabetes, particularly the role of diabetes and lipid abnormalities in atherosclerosis, and he has authored numerous scientific papers on these subjects. Richard O’Brien is President of the Asia Pacific Society of Atherosclerosis and Vascular Diseases, and is currently chair of the Australian Diabetes Society Expert Committee on Hyperlipidaemia. In addition to his University responsibilities, Richard O’Brien continues to be involved in direct patient care and maintains ongoing research interests in diabetes and atherosclerosis.

Steve has published over 220 articles and has an H-impact factor of 55, with more than 9,000 citations, including in foot disease in diabetes with research focus on biomarkers for foot ulceration and improving clinical care. He is also NADC Foot Network Hon. Clinical Chair and a DFA Committee member. In this keynote presentation he will provide an overview of the NDSS DA Foot Forward Program, its genesis and progress, and his role as Honorary Clinical Lead in the process.

He has been addressing the logistic and methodological challenges in the conduct of comparative effectiveness and safety studies with large multinational health records– with emphasis on establishing the acceptability of the real-world data based studies for regulatory bodies and public health policy makers. He has led more than 100 publications in highly acclaimed clinical research journals with 15,000+ citations in last 10 years.